This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
PLIVA Pharmaceuticals, Inc.
PLIVA Pharmaceuticals, Inc., a prominent player in the pharmaceutical industry, is headquartered in Croatia (HR) and operates extensively across Europe and North America. Founded in 1921, PLIVA has established itself as a leader in the development and manufacturing of generic and specialty pharmaceuticals, focusing on areas such as oncology, central nervous system disorders, and infectious diseases. With a commitment to innovation, PLIVA offers a diverse portfolio of high-quality products, including generic medications that provide cost-effective alternatives to branded drugs. The company is recognised for its robust research and development capabilities, which have led to significant advancements in drug formulation and delivery. As a subsidiary of Teva Pharmaceutical Industries, PLIVA continues to strengthen its market position, contributing to global health with its reliable and accessible pharmaceutical solutions.
DitchCarbon Score
How does PLIVA Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
PLIVA Pharmaceuticals, Inc.'s score of 82 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
PLIVA Pharmaceuticals, Inc., headquartered in Croatia (HR), currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Teva Pharmaceutical Industries Limited, which influences its climate commitments and emissions reporting. As part of its corporate family, PLIVA inherits climate initiatives and targets from Teva Pharmaceutical Industries Limited. This includes participation in various sustainability frameworks such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are cascaded from Teva at a level 2 relationship. However, specific reduction targets or achievements for PLIVA itself have not been disclosed. While no absolute emissions figures are provided, PLIVA's commitment to sustainability is aligned with its parent company's broader climate strategies. The absence of direct emissions data highlights the need for ongoing transparency and accountability in corporate climate commitments within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 438,420,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 613,541,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
PLIVA Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
